Recuvyra

RSS

fentanyl

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Recuvyra has expired following the marketing-authorisation holder’s decision not to apply for a renewal.

This EPAR was last updated on 12/07/2017

Authorisation details

Product details
Name
Recuvyra
Agency product number
EMEA/V/C/002239
Active substance
fentanyl
International non-proprietary name (INN) or common name
fentanyl
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QN02AB03
Publication details
Marketing-authorisation holder
Eli Lilly and Company Limited 
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
06/10/2011
Contact address
Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke
Hampshire RG24 9NL
United Kingdom

Product information

13/10/2016 Recuvyra - EMEA/V/C/002239 - IB/0009/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Nervous system

Therapeutic indication

For the control of pain associated with orthopaedic and soft tissue surgery in dogs.

Assessment history

How useful was this page?

Add your rating